Literature DB >> 16489370

New prospects and strategies for drug target discovery in neurodegenerative disorders.

Brian S Hilbush1, John H Morrison, Warren G Young, J Gregor Sutcliffe, Floyd E Bloom.   

Abstract

The future of neurodegenerative therapeutics development depends upon effective disease modification strategies centered on carefully investigated targets. Pharmaceutical research endeavors that probe for a much deeper understanding of disease pathogenesis, and explain how adaptive or compensatory mechanisms might be engaged to delay disease onset or progression, will produce the needed breakthroughs. Below, we discuss the prospects for new targets emerging out of the study of brain disease genes and their associated pathogenic pathways. We describe a general experimental paradigm that we are employing across several mouse models of neurodegenerative disease to elucidate molecular determinants of selective neuronal vulnerability. We outline key elements of our target discovery program and provide examples of how we integrate genomic technologies, neuroanatomical methods, and mouse genetics in the search for neurodegenerative disease targets.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16489370      PMCID: PMC1201320          DOI: 10.1602/neurorx.2.4.627

Source DB:  PubMed          Journal:  NeuroRx        ISSN: 1545-5343


  68 in total

1.  Genomic screen for QTLs underlying alcohol consumption in the P and NP rat lines.

Authors:  P Bice; T Foroud; R Bo; P Castelluccio; L Lumeng; T K Li; L G Carr
Journal:  Mamm Genome       Date:  1998-12       Impact factor: 2.957

Review 2.  What are the costs to society and to individuals regarding diagnostic procedures and care of patients with dementia?

Authors:  B Winblad; G Ljunggren; G Karlsson; A Wimo
Journal:  Acta Neurol Scand Suppl       Date:  1996

3.  Alpha-synuclein in Lewy bodies.

Authors:  M G Spillantini; M L Schmidt; V M Lee; J Q Trojanowski; R Jakes; M Goedert
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

4.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain.

Authors:  M DiFiglia; E Sapp; K O Chase; S W Davies; G P Bates; J P Vonsattel; N Aronin
Journal:  Science       Date:  1997-09-26       Impact factor: 47.728

5.  A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain.

Authors:  B De Strooper; W Annaert; P Cupers; P Saftig; K Craessaerts; J S Mumm; E H Schroeter; V Schrijvers; M S Wolfe; W J Ray; A Goate; R Kopan
Journal:  Nature       Date:  1999-04-08       Impact factor: 49.962

6.  Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.

Authors:  D Schenk; R Barbour; W Dunn; G Gordon; H Grajeda; T Guido; K Hu; J Huang; K Johnson-Wood; K Khan; D Kholodenko; M Lee; Z Liao; I Lieberburg; R Motter; L Mutter; F Soriano; G Shopp; N Vasquez; C Vandevert; S Walker; M Wogulis; T Yednock; D Games; P Seubert
Journal:  Nature       Date:  1999-07-08       Impact factor: 49.962

7.  Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation.

Authors:  S W Davies; M Turmaine; B A Cozens; M DiFiglia; A H Sharp; C A Ross; E Scherzinger; E E Wanker; L Mangiarini; G P Bates
Journal:  Cell       Date:  1997-08-08       Impact factor: 41.582

Review 8.  Genetic classification of primary neurodegenerative disease.

Authors:  J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

9.  Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1.

Authors:  L I Bruijn; M K Houseweart; S Kato; K L Anderson; S D Anderson; E Ohama; A G Reaume; R W Scott; D W Cleveland
Journal:  Science       Date:  1998-09-18       Impact factor: 47.728

10.  A quantitative trait locus for alcohol consumption in selectively bred rat lines.

Authors:  L G Carr; T Foroud; P Bice; T Gobbett; J Ivashina; H Edenberg; L Lumeng; T K Li
Journal:  Alcohol Clin Exp Res       Date:  1998-06       Impact factor: 3.455

View more
  5 in total

1.  Management of cognitive determinants in senile dementia of Alzheimer's type: therapeutic potential of a novel polyherbal drug product.

Authors:  Ananya Sadhu; Prabhat Upadhyay; Aruna Agrawal; Kaliappan Ilango; Dipankar Karmakar; Gur Prit Inder Singh; Govind Prasad Dubey
Journal:  Clin Drug Investig       Date:  2014-12       Impact factor: 2.859

Review 2.  Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders.

Authors:  Dharmendra Kumar Khatri; Amey Kadbhane; Monica Patel; Shweta Nene; Srividya Atmakuri; Saurabh Srivastava; Shashi Bala Singh
Journal:  Curr Res Pharmacol Drug Discov       Date:  2021-04-08

3.  Imbalance of a serotonergic system in frontotemporal dementia: implication for pharmacotherapy.

Authors:  D M Bowen; A W Procter; D M A Mann; J S Snowden; M M Esiri; D Neary; P T Francis
Journal:  Psychopharmacology (Berl)       Date:  2007-11-18       Impact factor: 4.530

4.  Structure Based Design and Molecular Docking Studies for Phosphorylated Tau Inhibitors in Alzheimer's Disease.

Authors:  Jangampalli Adi Pradeepkiran; P Hemachandra Reddy
Journal:  Cells       Date:  2019-03-19       Impact factor: 6.600

Review 5.  Perspective insights of repurposing the pleiotropic efficacy of statins in neurodegenerative disorders: An expository appraisal.

Authors:  Aditi Bhat; Harshita Dalvi; Harsha Jain; Nagarjun Rangaraj; Shashi Bala Singh; Saurabh Srivastava
Journal:  Curr Res Pharmacol Drug Discov       Date:  2020-12-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.